The introduction of new therapeutic agents in multiple myeloma (MM), including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, has improved the outcomes of patients but, in parallel, has changed the frequency and epidemiology of thrombotic events. Now, thrombosis is a significant cause of morbidity and mortality in MM patients, and optimal thromboprophylaxis is far from being reached. Moving from the recognition that the above issue represents an unmet clinical need, an Expert Panel assessed the scientific literature and composed a framework of recommendations for improving thrombosis control in patients candidates for active treatment for MM. The Panel generated clinical key questions using the criterion of clinical relevance through a Delphi process. It explored four domains, i.e., thrombotic risk factors and risk stratification, primary thromboprophylaxis, management of acute thrombotic events, and secondary thromboprophylaxis. The issued recommendations may assist hematologists in minimizing the risk of thrombosis and guarantee adherence to treatment in patients with MM candidates to active treatment.

中文翻译：

---

多发性骨髓瘤中的血栓形成：风险分层、抗血栓预防和急性事件的管理。来自特设专家小组的基于共识的立场文件。

在多发性骨髓瘤 (MM) 中引入新的治疗药物，包括蛋白酶体抑制剂、免疫调节药物和单克隆抗体，改善了患者的预后，但同时改变了血栓事件的频率和流行病学。现在，血栓形成是 MM 患者发病率和死亡率的重要原因，并且远未达到最佳的血栓预防。认识到上述问题代表了未满足的临床需求，专家小组评估了科学文献并制定了一个建议框架，以改善 MM 候选患者的血栓形成控制。专家组通过 Delphi 过程使用临床相关性标准生成临床关键问题。它探索了四个领域，即 血栓形成危险因素和风险分层、一级血栓预防、急性血栓形成事件的管理和二级血栓预防。发布的建议可能有助于血液学家最大限度地降低血栓形成的风险，并保证 MM 候选患者坚持接受积极治疗。